Navigating The Privacy Tightrope For CTIS

By Thomas Wicks, Head of Transparency Operations

With the projected enrollment of nearly 500,000 human research participants in trials based out of the European Union each year, the ethical safeguarding of personal data on such a massive scale poses a significant question. As the life sciences industry adjusts to the implementation of the new Clinical Trials Information System (CTIS), the effective management of data privacy, specifically through meticulous anonymization of personal information within clinical documents, becomes a pivotal determinant of success.

This comprehensive white paper delves into the intricate challenges, potential risks, suggested best practices, and forthcoming trends associated with the anonymization of personal data for CTIS submissions, which involves transforming identifiable information to safeguard privacy. The author also aims to provide valuable insights for biopharmaceutical organizations navigating this evolving landscape.

Unearth how all healthcare stakeholders will have to collaborate to build frameworks for responsible data sharing that lead to new life-changing therapies by accessing the full white paper below.